0.6580
-0.0220
(-3.24%)
As of 2:58:34 PM EDT. Market Open.
Insider Purchases Last 6 Months
| Shares | Transactions | |
|---|---|---|
| Purchases | 1,845,228 | 5 |
| Sales | 8,757 | 2 |
| Net Shares Purchased (Sold) | 1,836,471 | 7 |
| Total Insider Shares Held | 14.58M | -- |
| % Net Shares Purchased (Sold) | 14.40% | -- |
Net Institutional Purchases Prior Quarter to Latest Quarter
| Shares | |
|---|---|
| Net Shares Purchased (Sold) | -- |
| % Change in Institutional Shares Held | -- |
Insider Transactions Reported - Last Two Years
| Insider | Transaction | Type | Value | Date |
|---|---|---|---|---|
| BRENNAN KEVIN M Officer | Sale at price 0.98 per share. | Direct | 1,774 | Jan 2, 2025 |
| FRANKENFIELD CHRISTOPHER JAMES Chief Financial Officer | Sale at price 0.98 per share. | Direct | 6,841 | Jan 2, 2025 |
| RUSSO RENE PHARM.D. Chief Executive Officer | -- | Direct | -- | Dec 31, 2024 |
| BRENNAN KEVIN M Officer | -- | Direct | -- | Dec 31, 2024 |
| FRANKENFIELD CHRISTOPHER JAMES Chief Financial Officer | -- | Direct | -- | Dec 31, 2024 |
| LUPTAKOVA KATARINA M.D. Officer | -- | Direct | -- | Dec 31, 2024 |
| GILEAD SCIENCES INC Beneficial Owner of more than 10% of a Class of Security | Purchase at price 0.87 per share. | Direct | 1,525,021 | Dec 18, 2024 |
| GILEAD SCIENCES INC Beneficial Owner of more than 10% of a Class of Security | Purchase at price 1.48 per share. | Direct | 718,170 | Apr 2, 2024 |
| ATLAS VENTURE FUND XI L.P Beneficial Owner of more than 10% of a Class of Security | Sale at price 0.64 per share. | Indirect | 640 | Feb 8, 2024 |
| ATLAS VENTURE FUND XI L.P Beneficial Owner of more than 10% of a Class of Security | Sale at price 0.83 - 0.87 per share. | Indirect | 3,600 | Jan 12, 2024 |
Related Tickers
INAB IN8bio, Inc.
0.1474
-3.47%
SNSE Sensei Biotherapeutics, Inc.
0.3053
-2.46%
MRSN Mersana Therapeutics, Inc.
0.2750
-9.42%
IOBT IO Biotech, Inc.
0.8537
-2.77%
CTMX CytomX Therapeutics, Inc.
0.5061
+1.16%
IMRX Immuneering Corporation
1.2400
-3.88%
RLYB Rallybio Corporation
0.2550
+2.00%
KTTA Pasithea Therapeutics Corp.
1.6300
+51.21%
SPRC SciSparc Ltd.
0.2713
-1.52%
ALXO ALX Oncology Holdings Inc.
0.4790
-7.65%